In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on BioCryst (BCRX), with a price target of $13. The company’s shares closed yesterday at $8.79.
Fein wrote:
“Valuation and risks to achievement of price target. Our price target of $13 is based on the following risk-adjusted sum-of parts NPV-DCF: $10.9 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.2 for peramivir + $1.0 in cash. We assume a discount rate of 13.5%. Risks to our investment thesis and target price include: (1) failure of oral HAE agents in clinical trials; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity, due to prophylaxis market size or degree of long-term expansion, competition, or pricing.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.9% and a 48.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCryst with a $14 average price target, a 59.3% upside from current levels. In a report issued on February 25, Piper Jaffray also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
Based on BioCryst’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $27.43 million. In comparison, last year the company had a GAAP net loss of $19.54 million.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.
